VENUS REMEDIES LIMITED
VENUSREM · General/Diversified · NSE
₹1,161
Current Market Price
Fair Value (DCF)
₹1,366
Discount to FV
+17.7%
Updated just now
YieldIQ Score
65/100
Piotroski F-Score
6/9
Economic Moat
Wide
Confidence
56%
ROE
8.1%
Debt/Equity
0.00
WACC
11.1%
Market Cap
₹1,552 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
16.8%
Return on capital employed
EV / EBITDA
11.1×
Enterprise multiple
Debt / EBITDA
0.1×
Leverage vs earnings
Interest Coverage
1027.0×
EBIT covers interest
Current Ratio
3.31×
Short-term liquidity
Asset Turnover
1.07×
Revenue per ₹ of assets
Revenue CAGR (3Y)
11.6%
3-year revenue growth
Revenue CAGR (5Y)
7.0%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,161.05
Bear case
Margin of Safety -45.4%
Implied upside -31.2%
Base case
Margin of Safety +13.1%
Implied upside +15.0%
Bull case
Margin of Safety +27.5%
Implied upside +37.9%
Ratio Trends
VENUSREM · last 9 annual periods
ROE
8.1%
ROCE
16.8%
Operating Margin
—
Debt / Equity
0.00×
PE
19.6×
EV / EBITDA
2.8×
Historical Financials
VENUSREM · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹599 Cr | ₹553 Cr | ₹591 Cr | ₹653 Cr | ₹770 Cr | +6.5% |
| EBITDA | ₹70.1 Cr | ₹70.3 Cr | ₹71.2 Cr | ₹94.4 Cr | ₹160 Cr | +22.9% |
| EBIT | ₹36.9 Cr | ₹38.2 Cr | ₹44.7 Cr | — | — | +4.9% |
| PAT | ₹40.7 Cr | ₹26.6 Cr | ₹28.5 Cr | ₹45.3 Cr | ₹103 Cr | +26.0% |
| EPS (diluted) | ₹30.86 | ₹19.88 | ₹21.31 | — | — | -8.8% |
| CFO | ₹41.1 Cr | ₹36.6 Cr | ₹37.3 Cr | ₹86.5 Cr | ₹156 Cr | +39.5% |
| CapEx | — | ₹-7.8 Cr | ₹-13.5 Cr | ₹-18.1 Cr | ₹-37.7 Cr | — |
| FCF | — | ₹28.8 Cr | ₹23.8 Cr | ₹68.4 Cr | ₹118 Cr | +42.3% |
| Total Assets | ₹580 Cr | ₹601 Cr | ₹627 Cr | ₹716 Cr | ₹854 Cr | +10.2% |
| Total Debt | ₹42.8 Cr | ₹42.3 Cr | ₹41.3 Cr | ₹1.7 Cr | ₹12.4 Cr | -26.6% |
| Shareholders' Equity | ₹440 Cr | ₹460 Cr | ₹488 Cr | ₹561 Cr | ₹664 Cr | +10.8% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
VENUSREM vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
BETA BETA | — | — | Pending | 16.9% | — |
SYNCOMF SYNCOMF | — | — | Pending | 14.4% | — |
 SAKAR SAKAR HEALTHCARE LIMITED | -185.7%-65.0% upside | 40 | Above Fair Value | 10.0% | — |
JAGSNPHARM JAGSNPHARM | — | — | Pending | 15.6% | 28.1× |
 AMRUTANJAN AMRUTANJAN | — | — | Pending | 15.6% | 24.6× |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for VENUSREM in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. VENUS REMEDIES LIMITED (VENUSREM.NS) trades at 1161.05 vs a model fair value of 1366.36, a gap of 17.7%. Piotroski F-score: 6/9. Moat lab...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of VENUSREM →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for VENUSREM →
Compare
Head-to-head with peers
Compare VENUSREM side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse VENUSREMNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.